# Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

> **NCT02346032** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** refametinib

## Key facts

- **NCT ID:** NCT02346032
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-30
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-10-13
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346032, "Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02346032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*